1247-64-9
基本信息
化合物 T12536
Pregnenolone sulphate
Pregnenolone monosulfate
DIJBBUIOWGGQOP-OZIWPBGVSA-N
Pregn-5-en-20-one, 3-(sulfooxy)-, (3β)-
3β-Hydroxy-5-pregnen-20-one monosulfate
Di[(pregn-5-en-20-one)-3-yl] =sulfate ester
(3S,8S,9R,10S,13S,14R,17R)-17-acetyl-10,13-dimethyl-3-sulfooxy-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene
物理化学性质
| 密度 | 1.25±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C,stored under nitrogen |
| 溶解度 | DMSO: 62.5 mg/mL (157.61 mM) |
| 酸度系数(pKa) | -3.51±0.18(Predicted) |
| 形态 | Solid |
| 颜色 | White to off-white |
PREGNENOLONE MONOSULFATE价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/02/08 | HY-B1739 | PREGNENOLONE MONOSULFATE Pregnenolone monosulfate | 1247-64-9 | 5mg | 600元 |
| 2025/02/08 | HY-B1739 | PREGNENOLONE MONOSULFATE Pregnenolone monosulfate | 1247-64-9 | 10mM * 1mLin DMSO | 660元 |
| 2025/02/08 | HY-B1739 | PREGNENOLONE MONOSULFATE Pregnenolone monosulfate | 1247-64-9 | 10mg | 1000元 |
常见问题列表
|
CB1
|
Human Endogenous Metabolite
|
CB1 receptor stimulation increases brain Pregnenolone levels, which in turn exerts a negative feedback on the activity of the CB1 receptor antagonizing most of the known behavioral and somatic effects of THC. Pregnenolone likely acts as a signaling-specific negative allosteric modulator binding to a site distinct from that occupied by orthosteric ligands. Pregnenolone does not modify agonist binding but only agonist efficacy.
The effect of THC is significantly attenuated when slices are pre-treated with Pregnenolone 100 nM (15.1±1.8 % of inhibition). These effects are likely due to a pre-synaptic action of Pregnenolone. Thus, Pregnenolone blocks the increase in paired-pulse ratio (PPR) induced by THC but does not modify either the amplitude or the decay time of miniature EPSC (mEPSC).
Pregnenolone administration (2-6 mg/kg) blocks THC-induced food-intake in Wistar rats and in C57BL/6N mice, and blunts the memory impairment induced by THC in mice, but it does not modify these behaviors per se . Injections of Pregnenolone (2 and 4mg/kg) before each self-administration session reduce the intake of WIN 55,212-2 and reduce the break-point in a progressive ratio schedule.